Known symptomatic brain metastases
Patient has symptomatic brain metastases (i.e., metastases that are accompanied by neurological symptoms or that require treatment with corticosteroids)
Participants with symptomatic brain metastases that require active treatment are excluded
Known symptomatic brain metastases requiring ?10 mg/day of prednisolone (or its equivalent).
Symptomatic or uncontrolled brain metastases
Patients with brain metastases will be excluded if metastases have been symptomatic or actively treated within 4 weeks prior to enrollment
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids; patients with treated brain metastases are eligible as long as they completed prior brain radiation therapy more than 14 days prior to first dose of study therapy, are not experiencing seizures and are not receiving steroids for symptomatic brain metastases (for at least 7 days prior to first dose of study treatment)
Symptomatic or clinically active brain metastases
Patient has symptomatic brain or CNS metastases
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Presence of symptomatic brain metastases or brain metastases requiring escalating doses of corticosteroids to control neurological symptoms
Symptomatic brain metastases or leptomeningeal (LM) disease requiring corticosteroids for symptom management; asymptomatic brain metastases or LM will be allowed on study
Symptomatic or unstable brain metastases.
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Patients with symptomatic extrahepatic metastases
Symptomatic brain metastases
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Symptomatic brain metastases; any neurologic symptoms present must have resolved with local therapy by the time of administration of study drug
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Symptomatic brain metastases (baseline CT scan is not required in asymptomatic patients)
Symptomatic brain metastases
Symptomatic brain metastases
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
DOSE ESCALATION COHORT: Brain metastases: symptomatic, unstable, or disease requiring use of steroid treatment
DOSE EXPANSION COHORT: Brain metastases: symptomatic, unstable, or disease requiring use of steroid treatment
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Symptomatic brain or bone metastases; prior radiation and/or steroid therapy for brain or bone metastases (if applicable) must be completed >= 2 weeks prior to study enrollment
Patients with symptomatic brain metastases are excluded from this study
Histologically confirmed malignant melanoma with measurable metastases in the brain. Both asymptomatic and symptomatic patients.
Symptomatic or uncontrolled brain metastases;
Symptomatic or progressive brain metastases.
Patients with symptomatic brain metastases.
Symptomatic uncontrolled brain metastases
Participants with symptomatic or growing brain metastases less than 4 weeks prior to enrollment.
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
The participant has brain metastases that are symptomatic.
Known symptomatic or uncontrolled brain metastases or epidural disease
Symptomatic or clinically active brain metastases
Symptomatic brain metastases (prior treatment and stable metastases are allowed)
Symptomatic OR
Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
Subjects with symptomatic uncontrolled brain metastases;
Patients with known active or symptomatic brain metastases prior to vaccination.
Symptomatic brain metastases (patients with asymptomatic brain metastases may be eligible provided other criteria are met)
Symptomatic brain metastases.
Symptomatic brain metastases
Symptomatic brain metastases
Symptomatic brain metastases.
Symptomatic brain metastases.
Symptomatic brain metastases
Patient has symptomatic brain metastases, ie, presence of neurological symptoms or requiring treatment with corticosteroids, or CNS leukemia.
Patient with brain metastases that are symptomatic and/or require therapy.
Symptomatic and progressive or corticosteroid-requiring documented brain metastases
Patients who present with symptomatic brain radionecrosis after they have received radiosurgery for brain metastases from primary solid tumor including but not limited to lung, breast, colorectal cancer but excluding melanoma, choriocarcinoma, renal cell carcinoma or gliomas
Presence of symptomatic brain metastases at time of study consent process; patients with history of treated brain metastases are eligible if they are not symptomatic at the time of study enrollment
History of epilepsy, brain damage, use of anticonvulsants for seizure prevention, concurrently using ketamine, symptomatic brain metastases
Patients with history of epilepsy, brain damage, or symptomatic brain metastases.
Participants with symptomatic uncontrolled brain metastases; a scan to confirm the absence of brain metastases is not required
Patients with symptomatic brain metastases are excluded from this study.
Symptomatic brain metastases
